Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Neural Plasticity, enter your email address in the box below.

Neural Plasticity
Volume 2016, Article ID 9364091, 10 pages
http://dx.doi.org/10.1155/2016/9364091
Review Article

The Endocannabinoid System as a Therapeutic Target in Glaucoma

Elizabeth A. Cairns,1 William H. Baldridge,2,3 and Melanie E. M. Kelly1,3

1Department of Pharmacology, Dalhousie University, Halifax, NS, Canada B3H 4R2
2Department of Medical Neuroscience, Dalhousie University, Halifax, NS, Canada B3H 4R2
3Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada B3H 4R2

Received 10 July 2015; Accepted 10 November 2015

Academic Editor: Maurice Ptito

Copyright © 2016 Elizabeth A. Cairns et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Yazulla, “Endocannabinoids in the retina: from marijuana to neuroprotection,” Progress in Retinal and Eye Research, vol. 27, no. 5, pp. 501–526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Green, “Marihuana in ophthalmology: past, present and future,” Annals of Ophthalmology, vol. 11, no. 2, pp. 203–205, 1979. View at Google Scholar · View at Scopus
  3. C. Nucci, M. Bari, A. Spanò et al., “Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection,” Progress in Brain Research, vol. 173, pp. 451–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Järvinen, D. W. Pate, and K. Laine, “Cannabinoids in the treatment of glaucoma,” Pharmacology & Therapeutics, vol. 95, no. 2, pp. 203–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Chen, I. Matias, T. Dinh et al., “Finding of endocannabinoids in human eye tissues: implications for glaucoma,” Biochemical and Biophysical Research Communications, vol. 330, no. 4, pp. 1062–1067, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Lee and I. Goldberg, “Emerging drugs for ocular hypertension,” Expert Opinion on Emerging Drugs, vol. 16, no. 1, pp. 137–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. King, A. Azuara-Blanco, and A. Tuulonen, “Glaucoma,” British Medical Journal, vol. 346, Article ID f3518, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. A. Quigley, “Glaucoma,” The Lancet, vol. 377, no. 9774, pp. 1367–1377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, and M. Hussein, “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1268–1279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Matias, J. W. Wang, A. S. Moriello, A. Nieves, D. F. Woodward, and V. Di Marzo, “Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 75, no. 6, pp. 413–418, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Porcella, P. Casellas, G. L. Gessa, and L. Pani, “Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana,” Molecular Brain Research, vol. 58, no. 1-2, pp. 240–245, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Bisogno, I. Delton-Vandenbroucke, A. Milone, M. Lagarde, and V. Di Marzo, “Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina,” Archives of Biochemistry and Biophysics, vol. 370, no. 2, pp. 300–307, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Straiker, G. Maguire, K. Mackie, and J. Lindsey, “Localization of cannabinoid CB1 receptors in the human anterior eye and retina,” Investigative Ophthalmology & Visual Science, vol. 40, no. 10, pp. 2442–2448, 1999. View at Google Scholar · View at Scopus
  14. A. Straiker, N. Stella, D. Piomelli, K. Mackie, H. J. Karten, and G. Maguire, “Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 25, pp. 14565–14570, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Yazulla, K. M. Studholme, H. H. McIntosh, and D. G. Deutsch, “Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina,” The Journal of Comparative Neurology, vol. 415, no. 1, pp. 80–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Lu, A. Straiker, Q. Lu, and G. Maguire, “Expression of CB2 cannabinoid receptor mRNA in adult rat retina,” Visual Neuroscience, vol. 17, no. 1, pp. 91–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Porcella, C. Maxia, G. L. Gessa, and L. Pani, “The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein,” The European Journal of Neuroscience, vol. 12, no. 3, pp. 1123–1127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. W. D. Stamer, S. F. Golightly, Y. Hosohata et al., “Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues,” European Journal of Pharmacology, vol. 431, no. 3, pp. 277–286, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. E. M. López, P. Tagliaferro, E. S. Onaivi, and J. J. López-Costa, “Distribution of CB2 cannabinoid receptor in adult rat retina,” Synapse, vol. 65, no. 5, pp. 388–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Cécyre, N. Zabouri, F. Huppé-Gourgues, J.-F. Bouchard, and C. Casanova, “Roles of cannabinoid receptors type 1 and 2 on the retinal function of adult mice,” Investigative Ophthalmology and Visual Science, vol. 54, no. 13, pp. 8079–8090, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Bouskila, P. Javadi, C. Casanova, M. Ptito, and J.-F. Bouchard, “Müller cells express the cannabinoid CB2 receptor in the vervet monkey retina,” The Journal of Comparative Neurology, vol. 521, no. 11, pp. 2399–2415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Krishnan and N. Chatterjee, “Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation,” Glia, vol. 60, no. 11, pp. 1629–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zhong, L. Geng, Y. Njie, W. Feng, and Z.-H. Song, “CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 46, no. 6, pp. 1988–1992, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Sappington, T. Sidorova, D. J. Long, and D. J. Calkins, “TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure,” Investigative Ophthalmology & Visual Science, vol. 50, no. 2, pp. 717–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Kohno, H. Hasegawa, A. Inoue et al., “Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18,” Biochemical and Biophysical Research Communications, vol. 347, no. 3, pp. 827–832, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. D. Caldwell, S. S.-J. Hu, S. Viswanathan, H. Bradshaw, M. E. M. Kelly, and A. Straiker, “A GPR18-based signalling system regulates IOP in murine eye,” British Journal of Pharmacology, vol. 169, no. 4, pp. 834–843, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Macintyre, A. Dong, A. Straiker et al., “Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature,” European Journal of Pharmacology, vol. 735, no. 1, pp. 105–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Kumar, Z. Qiao, P. Kumar, and Z.-H. Song, “Effects of palmitoylethanolamide on aqueous humor outflow,” Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4416–4425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bouskila, P. Javadi, C. Casanova, M. Ptito, and J.-F. Bouchard, “Rod photoreceptors express GPR55 in the adult vervet monkey retina,” PLoS ONE, vol. 8, no. 11, Article ID e81080, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Di Marzo, “Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight,” Nature Neuroscience, vol. 14, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Piomelli, “More surprises lying ahead. The endocannabinoids keep us guessing,” Neuropharmacology B, vol. 76, pp. 228–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. S.-J. Hu, A. Arnold, J. M. Hutchens et al., “Architecture of cannabinoid signaling in mouse retina,” The Journal of Comparative Neurology, vol. 518, no. 18, pp. 3848–3866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Tsuboi, Y.-X. Sun, Y. Okamoto, N. Araki, T. Tonai, and N. Ueda, “Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase,” The Journal of Biological Chemistry, vol. 280, no. 12, pp. 11082–11092, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Alhouayek, J. Masquelier, and G. G. Muccioli, “Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy,” Drug Discovery Today, vol. 19, no. 3, pp. 295–304, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Blankman, G. M. Simon, and B. F. Cravatt, “A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol,” Chemistry & Biology, vol. 14, no. 12, pp. 1347–1356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. F. Woodward, R. L. Jones, and S. Narumiya, “International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress,” Pharmacological Reviews, vol. 63, no. 3, pp. 471–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Alhouayek and G. G. Muccioli, “COX-2-derived endocannabinoid metabolites as novel inflammatory mediators,” Trends in Pharmacological Sciences, vol. 35, no. 6, pp. 284–292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. C. A. Rouzer and L. J. Marnett, “Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways,” Chemical Reviews, vol. 111, no. 10, pp. 5899–5921, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. R. Kozak, S. W. Rowlinson, and L. J. Marnett, “Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33744–33749, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Maihöfner, U. Schlötzer-Schrehardt, H. Gühring et al., “Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes,” Investigative Ophthalmology & Visual Science, vol. 42, no. 11, pp. 2616–2624, 2001. View at Google Scholar · View at Scopus
  41. Y. F. Njie, Z. Qiao, Z. Xiao, W. Wang, and Z.-H. Song, “N-arachidonylethanolamide-induced increase in aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 49, no. 10, pp. 4528–4534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Di Marzo and S. Petrosino, “Endocannabinoids and the regulation of their levels in health and disease,” Current Opinion in Lipidology, vol. 18, no. 2, pp. 129–140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Giacoppo, G. Molino, M. Galuppo, and P. B. E. Mazzon, “Cannabinoids: new promising agents in the treatment of neurological diseases,” Molecules, vol. 19, no. 11, pp. 18781–18816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Nucci, V. Gasperi, R. Tartaglione et al., “Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats,” Investigative Ophthalmology & Visual Science, vol. 48, no. 7, pp. 2997–3004, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. W.-K. Ju, K.-Y. Kim, and A. H. Neufeld, “Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia,” Experimental Eye Research, vol. 77, no. 2, pp. 137–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Carta, C. T. Supuran, and A. Scozzafava, “Novel therapies for glaucoma: a patent review 2007–2011,” Expert Opinion on Therapeutic Patents, vol. 22, no. 1, pp. 79–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. P. L. Kaufman and C. A. Rasmussen, “Advances in glaucoma treatment and management: outflow drugs,” Investigative Ophthalmology & Visual Science, vol. 53, no. 5, pp. 2495–2500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Zhang, L. Zhang, and R. N. Weinreb, “Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma,” Nature Reviews Drug Discovery, vol. 11, no. 7, pp. 541–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Porcella, C. Maxia, G. L. Gessa, and L. Pani, “The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies,” The European Journal of Neuroscience, vol. 13, no. 2, pp. 409–412, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Tomida, A. Azuara-Blanco, H. House, M. Flint, R. G. Pertwee, and P. J. Robson, “Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study,” Journal of Glaucoma, vol. 15, no. 5, pp. 349–353, 2006. View at Publisher · View at Google Scholar
  51. P. Robson, “Therapeutic aspects of cannabis and cannabinoids,” The British Journal of Psychiatry, vol. 178, pp. 107–115, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. J. C. Merritt, D. D. Perry, D. N. Russell, and B. F. Jones, “Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.,” Journal of Clinical Pharmacology, vol. 21, no. 8-9, supplement, pp. 467S–471S, 1981. View at Google Scholar · View at Scopus
  53. J. C. Merritt, W. J. Crawford, P. C. Alexander, A. L. Anduze, and S. S. Gelbart, “Effect of marihuana on intraocular and blood pressure in glaucoma,” Ophthalmology, vol. 87, no. 3, pp. 222–228, 1980. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Y. Chien, R.-F. Wang, T. W. Mittag, and S. M. Podos, “Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys,” Archives of Ophthalmology, vol. 121, no. 1, pp. 87–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. F. Njie, A. Kumar, Z. Qiao, L. Zhong, and Z.-H. Song, “Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 47, no. 5, pp. 1999–2005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Z.-H. Song and C.-A. Slowey, “Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2,” The Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 136–139, 2000. View at Google Scholar · View at Scopus
  57. B. D. Hudson, M. Beazley, A.-M. Szczesniak, A. Straiker, and M. E. M. Kelly, “Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists,” The Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 3, pp. 757–767, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. A.-M. Szczesniak, Y. Maor, H. Robertson, O. Hung, and M. E. M. Kelly, “Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 5, pp. 427–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. M. Civan, “Formation of the aqueous humor: transport components and their integration,” Current Topics in Membranes, vol. 62, pp. 1–45, 2008. View at Google Scholar
  60. M. P. Fautsch and D. H. Johnson, “Aqueous humor outflow: what do we know? Where will it lead us?” Investigative Ophthalmology & Visual Science, vol. 47, no. 10, pp. 4181–4187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. F. Njie, F. He, Z. Qiao, and Z.-H. Song, “Aqueous humor outflow effects of 2-arachidonylglycerol,” Experimental Eye Research, vol. 87, no. 2, pp. 106–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Liang, D. F. Woodward, V. M. Guzman et al., “Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes,” British Journal of Pharmacology, vol. 154, no. 5, pp. 1079–1093, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. S. D. Smid, “Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: a closer look at the agonist properties of bimatoprost and the prostamides,” Clinical Ophthalmology, vol. 3, no. 1, pp. 663–670, 2009. View at Google Scholar · View at Scopus
  64. D. McHugh, S. S. J. Hu, N. Rimmerman et al., “N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor,” BMC Neuroscience, vol. 11, article 44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. E. R. Tamm, L. Schmetterer, and F. Grehn, “Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper,” Cell and Tissue Research, vol. 353, no. 2, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Qu, D. Wang, and C. L. Grosskreutz, “Mechanisms of retinal ganglion cell injury and defense in glaucoma,” Experimental Eye Research, vol. 91, no. 1, pp. 48–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. R. Hara and S. H. Snyder, “Cell signaling and neuronal death,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 117–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Crandall, S. Matragoon, Y. M. Khalifa et al., “Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma,” Ophthalmic Research, vol. 39, no. 2, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. A. B. El-Remessy, I. E. Khalil, S. Matragoon et al., “Neuroprotective effect of (–)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite,” American Journal of Pathology, vol. 163, no. 5, pp. 1997–2008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Pinar-Sueiro, J. Á. Zorrilla Hurtado, P. Veiga-Crespo, S. C. Sharma, and E. Vecino, “Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat,” Experimental Eye Research, vol. 110, pp. 55–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. J. E. Slusar, E. A. Cairns, A.-M. Szczesniak, H. B. Bradshaw, A. Di Polo, and M. E. M. Kelly, “The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy,” Neuropharmacology C, vol. 72, pp. 116–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Sakai, T. Tanaka, M. Seki et al., “Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice,” Neuroscience Research, vol. 65, no. 4, pp. 319–325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Mori, T. Ishii, T. Kuroki et al., “The prostanoid EP2 receptor agonist ONO-AE1-259-01 protects against glutamate-induced neurotoxicity in rat retina,” European Journal of Pharmacology, vol. 616, no. 1–3, pp. 64–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. N. N. Osborne, G.-Y. Li, D. Ji et al., “Expression of prostaglandin PGE2 receptors under conditions of aging and stress and the protective effect of the EP2 agonist butaprost on retinal ischemia,” Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3238–3248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Y. Xu and C. Chen, “Endocannabinoids in synaptic plasticity and neuroprotection,” The Neuroscientist, vol. 21, no. 2, pp. 152–168, 2015. View at Publisher · View at Google Scholar
  76. M. Roh, Y. Zhang, Y. Murakami et al., “Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma,” PLoS ONE, vol. 7, no. 7, Article ID e40065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Vohra, J. C. Tsai, and M. Kolko, “The role of inflammation in the pathogenesis of glaucoma,” Survey of Ophthalmology, vol. 58, no. 4, pp. 311–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. X. Yang, C. Luo, J. Cai et al., “Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina,” Investigative Ophthalmology & Visual Science, vol. 52, no. 11, pp. 8442–8454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Zhang and C. Chen, “Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation,” The Journal of Biological Chemistry, vol. 283, no. 33, pp. 22601–22611, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Drago, S. Valzelli, I. Emmi, A. Marino, C. C. Scalia, and V. Marino, “Latanoprost exerts neuroprotective activity in vitro and in vivo,” Experimental Eye Research, vol. 72, no. 4, pp. 479–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. W. M. Jay and K. Green, “Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes,” Archives of Ophthalmology, vol. 101, no. 4, pp. 591–593, 1983. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Plange, K. O. Arend, M. Kaup et al., “Dronabinol and retinal hemodynamics in humans,” American Journal of Ophthalmology, vol. 143, no. 1, pp. 173–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Gagliano, E. Ortisi, L. Pulvirenti et al., “Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial,” Investigative Ophthalmology and Visual Science, vol. 52, no. 9, pp. 6096–6100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Hosseini, F. A. Lattanzio, P. B. Williams, D. Tibbs, S. S. Samudre, and R. C. Allen, “Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects,” Experimental Eye Research, vol. 82, no. 5, pp. 753–759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Fernández-Suárez, M. Celorrio, J. I. Riezu-Boj et al., “The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model,” Neurobiology of Aging, vol. 35, no. 11, pp. 2603–2616, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Ghosh, L. E. Wise, Y. Chen et al., “The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model,” Life Sciences, vol. 92, no. 8-9, pp. 498–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. P. S. Katz, J. K. Sulzer, R. A. Impastato, S. X. Teng, E. K. Rogers, and P. E. Molina, “Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injur,” Journal of Neurotrauma, vol. 32, no. 5, pp. 297–306, 2015. View at Publisher · View at Google Scholar
  88. D. Wootten, A. Christopoulos, and P. M. Sexton, “Emerging paradigms in GPCR allostery: implications for drug discovery,” Nature Reviews Drug Discovery, vol. 12, no. 8, pp. 630–644, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. M. R. Price, G. L. Baillie, A. Thomas et al., “Allosteric modulation of the cannabinoid CB1 receptor,” Molecular Pharmacology, vol. 68, no. 5, pp. 1484–1495, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. R. G. Pertwee, “The pharmacology of cannabinoid receptors and their ligands: an overview,” International Journal of Obesity, vol. 30, supplement 1, pp. S13–S18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. R. A. Ross, “Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor,” British Journal of Pharmacology, vol. 152, no. 5, pp. 565–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. F. A. Pamplona, J. Ferreira, O. M. de Lima Jr. et al., “Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 51, pp. 21134–21139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. G. L. Baillie, J. G. Horswill, S. Anavi-Goffer et al., “CB1 receptor allosteric modulators display both agonist and signaling pathway specificity,” Molecular Pharmacology, vol. 83, no. 2, pp. 322–338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Riordan-Eva, “Anatomy & embryology of the eye,” in Vaughan & Asbury's General Ophthalmology, P. Riordan-Eva and E. T. Cunningham, Eds., The McGraw-Hill Companies, New York, NY, USA, 18th edition, 2011. View at Google Scholar